Ayvakit (avapritinib) — CareFirst (Caremark)
Myeloid/lymphoid neoplasms with eosinophilia
Initial criteria
- Disease harbors a PDGFRA D842V mutation which is resistant to imatinib
- Disease is FIP1L1-PDGFRA rearrangement-positive
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months